Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Alina Markova,Alexander Pan,Stephen Dusza,Arifa Chowdhury,Oluwaseun Kukoyi,Miguel-Angel Perales,Mario Lacouture,Susan Prockop,Doris M Ponce

doi:10.1182/blood-2021-144743

Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Alina Markova, Alexander Pan + Show 7 more

Open Access

https://doi.org/10.1182/blood-2021-144743

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 5

Affiliation: Memorial Sloan Kettering Cancer Center

#Composite Assessment Of Index Lesion Severity #Cutaneous cGvHD + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Full Text